Sustainable development
Qizheng Tibetan Medicine Releases Preliminary Report on First-Half Performance: Operating Profit Up 13.69% Year-on-Year
Release time:
2025-07-29 11:38
On the evening of July 28, Qizheng Tibetan Medicine (002287.SZ) released its preliminary report on the first half of 2025 performance. The report showed that in the first half of 2025, the company’s operating performance grew steadily, with total operating revenue reaching RMB 1.175 billion, an increase of 16.36% over the same period last year; operating profit amounted to RMB 417 million, up 13.69% year-on-year; net profit attributable to shareholders of the listed company reached RMB 358 million, up 9.94% year-on-year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses came in at RMB 289 million, up 27.20% year-on-year.
As a leading modern Tibetan medicine enterprise, Qizheng Tibetan Medicine has consistently focused on the research and development, production, and sales of Tibetan medicines. Its core business covers areas such as topical pain-relief medications, oral Tibetan formulations, and traditional Chinese medicines. Currently, the company has built an extensive product portfolio, including a range of topical products represented by Xiao Tong Tie Gao (Pain-Relieving Plaster), Qing Peng Ointment, Bai Mai Ointment, and Tie Bang Chui Pain-Relieving Ointment, as well as oral Tibetan and traditional Chinese medicine products represented by Hong Hua Ru Yi Wan (Red Flower Wish Pill), Ru Yi Zhen Bao Pian (Wish Treasure Tablets), Shi Wei Long Dan Hua Capsules, Shi Wei Long Dan Hua Granules, and Ren Qing Mang Jue Capsules. Meanwhile, the company holds 141 drug approval numbers, among which 3 are classified as state-secret technologies (secret level) and 25 are exclusive products. Its product lineup covers various therapeutic areas, including the musculoskeletal system, nervous system, respiratory system, digestive system, urinary system, as well as cardiovascular and cerebrovascular diseases, gynecology, pediatrics, and dermatology.
It is worth noting that public information shows that in the first half of 2025, the company’s Class 1.1 innovative traditional Chinese medicine, Xiao’er Re Li Qing Granules, received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, marking a significant step forward for the company in the field of pediatric innovative traditional Chinese medicine. Thanks to its outstanding performance in R&D innovation and its remarkable contributions to promoting the modernization of Tibetan medicine, the company has been ranked among the Top 50 on the “2025 China Traditional Chinese Medicine R&D Strength Ranking,” placing 26th. The intelligent factory for topical Tibetan medicine preparations at the company’s Linzhi Manufacturing Center has been awarded the title of “Excellent-Level Intelligent Factory” by the Ministry of Industry and Information Technology. As the only Tibetan medicine enterprise to receive the title of “National Advanced Collective in the Industrial and Information Technology System,” the company has brought honor to the Tibetan medicine industry.
Reporting media: Shanghai Securities Journal·China Securities Network
Report link: https://www.cnstock.com/commonDetail/477820
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO